您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Hydroxyurea(Hydroxycarbamide)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Hydroxyurea(Hydroxycarbamide)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Hydroxyurea(Hydroxycarbamide)图片
CAS NO:127-07-1
规格:≥98%
包装与价格:
包装价格(元)
1g电议
2g电议
5g电议
10g电议
50g电议
100g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)76.05
FormulaCH4N2O2
CAS No.127-07-1
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 15 mg/mL (197.2 mM)
Water: 15 mg/mL (197.2 mM)
Ethanol: <1 mg/mL
Other info

Chemical Name: 1-hydroxyurea

InChi Key: VSNHCAURESNICA-UHFFFAOYSA-N

InChi Code: InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

SMILES Code: O=C(N)NO

SynonymsNCI-c04831, NSC-32065; NCI c04831, NSC 32065; NCIc04831, NSC32065; Biosupressin; Carbamoyl oxime; Droxia; Hydroxycarbamide
实验参考方法
In Vitro

In vitro activity: Hydroxyurea can inhibit HIV-1 replication. In vitro experiments have shown that the 90% inhibitory concentration (IC90) of hydroxyurea for laboratory strains of HIV-1 in activated PBMC is 0.4 mM. Hydroxyurea was also found to be synergistic with the nucleoside reverse transcriptase inhibitor didanosine and to inhibit HIV-1 replication in activated PBMC; this inhibition may be due to a reduction in deoxynucleoside triphosphate pool sizes. Hydroxyurea has been shown to sensitize didanosine-resistant mutants. Hydroxyurea has demonstrated activity in the treatment of sickle cell anemia by increasing the production of fetal hemoglobin, which reduces hemolysis in patients with this disease. Hydroxyurea exerts its cytostatic effect through inhibition of ribonucleotide reductase—the rate-limiting enzyme responsible for the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis. As a result, cellular division is arrested in the S phase.


Cell Assay: Erythroid cells obtained from peripheral blood of the same patients(Thirteen β-Thal/HbE patients are treated with hydroxyurea orally for 2 years at a starting dose of 5 mg/kg/day for 5 days/week with escalation to a maximum of 10 mg/kg/day) 1 year after they had stopped hydroxyurea treatment are treated with hydroxyurea in vitro.Treatment of cells performs in primary culture with 30 μM hydroxyurea for 96 hours.

In VivoHydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice.
Animal modelFemale athymic (nu/nu) nude mice(used for xenograft model)
Formulation & DosageDissolved in saline; 1500 mg/kg; i.p. injection
References

Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7; Clin Infect Dis. 2000 Jun;30 Suppl 2:S143-50.